The Ministry of Health of the Republic of Indonesia has officially entered into a strategic collaboration with global biopharmaceutical company Takeda to build an independent domestic plasma-derived medicinal product (PDMP) ecosystem. This step is taken as a concrete effort by the government to strengthen national health system resilience, which has so far relied on imported supplies.
In this ambitious project, the initial investment reaches USD 30 million, equivalent to Rp539 billion. These funds will be allocated to infrastructure development and production capacity, which is expected to meet the demand for plasma-based therapies across various healthcare facilities in Indonesia.
Through this partnership, the government aims to increase public accessibility to high-quality treatments. Mastering technology and establishing a domestic plasma-derived medicinal product production ecosystem are seen as crucial keys to ensuring the sustainable availability of essential medicines for patients requiring plasma therapy.
